OPSENS' SAVVYWIRE™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando
QUEBEC CITY, Nov. 8, 2021 /CNW/ - OpSens Inc. ("OpSens"or the "Company") (TSX:OPS)(OTCQX:OPSSF), a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology market, announced that its SavvyWire, developed specifically for transcatheter aortic valve replacement ("TAVR"), was featured in four presentations by leading medical specialists during the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meetingheld from November 4-6, 2021 in Orlando, Florida.
- QUEBEC CITY, Nov. 8, 2021 /CNW/ - OpSens Inc. ("OpSens"or the "Company") (TSX:OPS)(OTCQX:OPSSF), a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology market, announced that its SavvyWire, developed specifically for transcatheter aortic valve replacement ("TAVR"), was featured in four presentations by leading medical specialists during the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meetingheld from November 4-6, 2021 in Orlando, Florida.
- Integration of this unique technology within a dedicated TAVR wire with live hemodynamic assessment could bring meaningful value to TAVR operators.
- I am expecting that sensor-guided TAVR procedure using the OpSens SavvyWire will become the new standard of care in the near future".
- OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.